MS Pharma Group signs exclusive biosimilars collaboration agreement with HeteroJanuary 27, 2026 | Tuesday | NewsSignificant step towards strengthening Algeria's biopharmaceutical ecosystemMS Pharma Group, a leading regional pharmaceutical company in the Middle East and North Africa (MENA) region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localise five established biosimilars across key therapeutic areas, including oncology, immunology and hematology. The exclusive agreement will be implemented through El Kendi – MS Pharma Group's affiliate in Algeria and Hetero Biopharma – a subsidiary of Hetero Group. "Strategic partnerships like this enable us to build durable regional capabilities and create meaningful, long-term impact for patients and health systems across the MENA region," said Kalle Känd, CEO of MS Pharma. We are pleased to enter into a strategic partnership with MS Pharma, a well-established and trusted healthcare leader in the Middle East and beyond. This collaboration marks an important step in advancing healthcare delivery and addressing unmet medical needs across the Middle East, Algeria, and other key markets", said Dr Vamsi Krishna, MD, Hetero Group.

Source: The North Africa Journal January 27, 2026 12:17 UTC